Abstract 2503: The Influende of Renal Function on Clinical Outcome and Response to Beta-Blockade in Systolic Heart Failure: Insights from MERIT-HF
Objective: We analyzed the data from MERIT-HF in order to determine the impact of renal function on absolute risk for and type of clinical events, and to study any interaction between renal function and the risk reducing effect and tolerability of metoprolol CR/XL in systolic HF
Methods: Glomerular filtration rate was estimated using the simplified MDRD formula (eGFRMDRD). Patients were divided in four subgroups according to defined cut off points for renal dysfunction: Normal renal function: eGFRMDRD ≥ 90 (n = 411); mild renal failure ≥ 60 < 90 (n = 2085); moderate renal failure ≥30 < 60 (n = 1387); and severe renal failure < 30 ml/min/1.73m2 BSA (n = 82).
Results : Table⇓ shows one year risk per patient year of follow-up (placebo). Risk reduction with metoprolol CR/XL was consistent regardless of renal function Metoprolol CR/XL was well tolerated in renal failure.
The risk for death and hospitalizations from worsening HF increased steeply with a decrease in renal function.
The beneficial effect of metoprolol CR/XL on outcomes was maintained regardless of renal function.
Metoprolol CR/XL was well tolerated in renal failure.